01/18/23 8:00 PMNasdaq : BLUE offeringhigh shortbluebird bio, Inc. Announces Pricing of $120 Million Public Offering of Common StockGoldman Sachs& Co. LLC and J.P. Morgan Securities LLC are acting as joint book running managers for the offering. A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC. Copies of the final prospectus supplement and accompanying prospectus relating to the offering may be obtained, when available, by contacting...RHEA-AIneutral
01/18/23 6:43 AMNasdaq : BLUE offeringhigh shortbluebird bio, Inc. Announces Proposed Public Offering of Common StockGoldman Sachs& Co. LLC and J.P. Morgan Securities LLC are acting as joint book running managers for the offering. A preliminary prospectus supplement describing the terms of the offering will be filed with the SEC and will form a part of the effective registration statement. Copies of the preliminary prospectus supplement and accompanying prospectus...RHEA-AIneutral
01/09/23 7:00 AMNasdaq : BLUE high shortbluebird bio Provides Update on Commercial Launch Progress, Program Milestones and 2023 Financial Outlook Ahead of Company Presentation at 41st Annual J.P. Morgan Healthcare Conferencebluebird bio, Inc. today announced updates to be presented at the 41 st Annual J.P. Morgan Healthcare conference including commercial launch progress, 2023 program milestones and financial outlook. CEO Andrew Obenshain is scheduled to speak on Thursday, January 12 at 7:30 a.m. PT. “In 2022, bluebird bio emerged as a commercial stage gene therapy company, with a...RHEA-AIpositive
01/06/23 7:30 AMNasdaq : BLUE high shortbluebird bio Sells Second Priority Review Voucher for $95 Millionbluebird bio, Inc. today announced that it has entered into a definitive agreement to sell its second Rare Pediatric Disease Priority Review Voucher for $95 million. bluebird bio was granted two PRVs upon the US Food and Drug Administration approvals of ZYNTEGLO ® for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red...RHEA-AIvery positive
01/05/23 8:00 AMNasdaq : BLUE conferenceshigh shortbluebird bio to Present at the 41st Annual J.P. Morgan Healthcare Conferencebluebird bio, Inc. today announced that Andrew Obenshain, chief executive officer, bluebird bio, will present a corporate update at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 7:30AM PT. To access the live webcast of bluebird bio’ s presentation, please visit the“ Events& Presentations” page within the Investors& Media section...RHEA-AIneutral
01/03/23 8:00 AMNasdaq : BLUE managementhigh shortbluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officerbluebird bio, Inc. today announced that Joseph Vittiglio, JD, has been appointed Chief Business and Legal Officer. “Joe’ s appointment, including his decades of legal and business development expertise in biotechnology and across the life sciences industry, solidifies and strengthens our management team as we continue our transition into a commercial stage...RHEA-AIvery positive
12/19/22 7:30 AMNasdaq : BLUE high shortFDA Lifts Partial Clinical Hold for bluebird bio’s Sickle Cell Disease (SCD) Studies for Patients Under the Age of 18bluebird bio, Inc. today announced that the U.S. Food and Drug Administration lifted its partial clinical hold for patients under the age of 18 in studies evaluating lovotibeglogene autotemcel for sickle cell disease. “We are very pleased to have addressed the FDA’ s questions and resolved the partial clinical hold,” said Richard Colvin, M.D., Ph.D., chief medical...RHEA-AIvery positive
12/10/22 11:30 AMNasdaq : BLUE high shortNew Data from bluebird bio’s Gene Therapies for Transfusion-Dependent Beta-Thalassemia and Sickle Cell Disease Presented at 64th ASH Annual MeetingToday new and updated data from bluebird bio inc.’ s gene therapy programs in beta-thalassemia and sickle cell disease were presented at the 64 th American Society of Hematology Annual Meeting and Exposition. The ASH Annual Meeting is taking place December 10-13, 2022, in New Orleans and virtually. Today, with the first FDA approved gene therapy for...RHEA-AIneutral
11/30/22 7:00 AMNasdaq : BLUE high shortbluebird bio Sells Priority Review Voucher for $102 Millionbluebird bio, Inc. today announced that it has entered into a definitive agreement to sell a Rare Pediatric Disease Priority Review Voucher for $102 million. bluebird was granted two PRVs upon the US Food and Drug Administration approvals of ZYNTEGLO ® for the treatment of beta-thalassemia in adult and pediatric patients requiring regular red blood cell...RHEA-AIvery positive
11/07/22 7:00 AMNasdaq : BLUE earningshigh shortbluebird bio Reports Third Quarter 2022 Financial Results and Highlights Operational Progressbluebird bio, Inc. today reported financial results and business highlights for the third quarter ended September 30, 2022 and shared recent operational progress. "The third quarter officially launched bluebird bio as a commercial gene therapy company, following FDA approvals of ZYNTEGLO for beta-thalassemia and SKYSONA for cerebral...RHEA-AIvery positive